IVIg

静注用免疫グロブリン

Wikipedia preview

出典(authority):フリー百科事典『ウィキペディア（Wikipedia）』「2012/10/17 13:42:52」(JST)

wiki en

[Wiki en表示]

Intravenous immunoglobulin (IVIG) is a blood product administered intravenously. It contains the pooled, polyvalent, IgG (immunoglobulin (antibody) G) extracted from the plasma of over one thousand blood donors. IVIG's effects last between 2 weeks and 3 months. It is mainly used as treatment in three major categories:

• Immune deficiencies such as X-linked agammaglobulinemia, hypogammaglobulinemia (primary immune deficiencies), and acquired compromised immunity conditions (secondary immune deficiencies) featuring low antibody levels.
• Autoimmune diseases, e.g. Immune thrombocytopenia ITP, and Inflammatory diseases, e.g. Kawasaki disease.
• Acute infections.

Researchers are currently investigating the use of IVIG in early Alzheimer's disease, with encouraging results.

IVIG use

IVIG is given as a plasma protein replacement therapy (IgG) for immune deficient patients who have decreased or abolished antibody production capabilities. In these immune deficient patients, IVIG is administered to maintain adequate antibody levels to prevent infections and confers a passive immunity. Treatment is given every 3–4 weeks. In the case of patients with autoimmune disease, IVIG is administered at a high dose (generally 1-2 grams IVIG per kg body weight) to attempt to decrease the severity of the autoimmune diseases such as Dermatomyositis. Currently, IVIg is being increasingly used off-label in a number of pathological conditions; the increasing world-wide usage of IVIg may lead to shortages of this beneficial drug.

IVIG is useful in some acute infection cases such as pediatric HIV infection as well as autoimmune, such as Guillain–Barré syndrome.

As asthma treatment

Asthma is a condition which can have many causes. In patients with both immune abnormalities and an infection causing asthma, the triggering infection could be eliminated with IGIV therapy. However, most asthma patients have a normal immune system and their asthma is the result of lower airway inflammation which can be managed in the context of a healthy immune system. Despite popularity of use, IGIV is not recommended for recurrent asthma infections unless the patient presents an impaired response to vaccine immunizations or natural infections.

Mechanism of action

The precise mechanism by which IVIG suppresses harmful inflammation has not been definitively established but is believed to involve the inhibitory Fc receptor. However, the actual primary target(s) of IVIG in autoimmune disease are still unclear. IVIG may work via a multi-step model where the injected IVIG first forms a type of immune complex in the patient. Once these immune complexes are formed, they interact with activating Fc receptors on dendritic cells which then mediate anti-inflammatory effects helping to reduce the severity of the autoimmune disease or inflammatory state.

Additionally, the donor antibody may bind directly with the abnormal host antibody, stimulating its removal. Alternatively, the massive quantity of antibody may stimulate the host's complement system, leading to enhanced removal of all antibodies, including the harmful ones. IVIG also blocks the antibody receptors on immune cells (macrophages), leading to decreased damage by these cells, or regulation of macrophage phagocytosis.

IVIG may also regulate the immune response by reacting with a number of membrane receptors on T cells, B cells, and monocytes that are pertinent to autoreactivity and induction of tolerance to self.

A recent report stated that IVIG application to activated T cells leads to their decreased ability to engage microglia. As a result of IVIG treatment of T cells, the findings showed reduced levels of tumor necrosis factor-alpha and interleukin-10 in T cell-microglia co-culture. The results add to the understanding of how IVIG may affect inflammation of the central nervous system in autoimmune inflammatory diseases.

IVIG notes

• IVIG is an infusion of IgG antibodies only. Therefore, peripheral tissues that are defended mainly by IgA antibodies, such as the eyes, lungs, gut and urinary tract are not fully protected by the IVIG treatment.
• XLA patients are immune to the most dangerous adverse effect, anaphylactic shock, as they do not have the antibodies to react against the treatment. Anaphylactic shock has a higher chance to occur in IgA deficient patients which do have other antibody types.
• In case of recurring side effects, it is recommended to slow the pace of the IVIG administration and to reduce the dosage. It is also advisable to change IVIG brand, as some people react against a specific brand.
• If the patient is diabetic, he should take into consideration the medium in which the antibodies are solubilized in the IVIG treatment, as some brand solubilize antibodies with high concentrated sugars (such as sucrose and maltose).
• U.S. Food and Drug Administration (FDA) guidelines for IVIG state the product should be:
  • Prepared out of at least 1,000 different human donors.
  • All four IgG subgroups (1-4) should be present.
  • The IgG should maintain biological activity and lifetime of at least 21 days.
  • Does not contain samples which are HIV, hepatitis B, hepatitis C positive.
  • Screened and treated in a manner that destroys viruses.
• IVIG is also considered a modulator of the immune system and was shown to be beneficial in treating numerous autoimmune diseases such as relapsing and remitting multiple sclerosis (MS), myasthenia gravis, pemphigus, polymyositis (PM), dermatomyositis (DM), Wegener's granulomatosis (WG), Churg-Strauss syndrome, chronic inflammatory demyelinating polyneuropathy (CIDP) and more.
• IVIG can be given to pregnant women.
• IVIG is also used as a treatment for unexplained recurring miscarriages. The effectiveness of the therapy is controversial.
• IVIG cost is stable but over $75/g. ($15,000 for a 100 kg (220 lbs) person at 2g/kg)

IVIG dose

Dosage of IVIG is dependent on indication.

For primary immune dysfunction 100 to 400 mg/kg of body weight every 3 to 4 weeks is implemented.

For neurological and autoimmune diseases 2 grams per kilogram of body weight is implemented for three to six months over a five day course once a month. Then maintenance therapy of 100 to 400 mg/kg of body weight every 3 to 4 weeks follows.

FDA-approved indications

• Allogeneic bone marrow transplant
• Chronic lymphocytic leukemia
• Common variable immunodeficiency (CVID) a group of approximately 150 primary immunodeficiencies (PIDs), which have a common set of features (including hypogammaglobulinemia) but which have different underlying causes
• Idiopathic thrombocytopenic purpura
• Pediatric HIV
• Primary immunodeficiencies
• Kawasaki disease
• Chronic inflammatory demyelinating polyneuropathy (CIDP). Only the "Gamunex" brand manufactured by Talecris is approved for CIDP (in 2008), under the U.S. Orphan Drug law provisions
• Kidney transplant with a high antibody recipient or with an ABO incompatible donor

In 2004 the FDA approved the Cedars-Sinai IVIG Protocol which has been 90-95% successful in removing antibodies from the blood of kidney transplant recipients so that they can accept a living donor kidney from any healthy donor no matter blood type (ABO incompatible) or tissue match.

In Phase III testing in the US (as of December 2008)

• Alzheimer's Disease

Early experimental results in 2012 from a small clinical trial in humans have shown hints that it may protect against the progression of Alzheimer's Disease.

According to experts at the Alzheimer's Association International Conference 2012 in Vancouver, the immune therapy called IVIG/Gammagard is first long-term treatment shown to halt the progression of Alzheimer's disease

Off-label uses

• Alzheimer's disease
• Autism
• Capillary leak syndrome
• Chronic fatigue syndrome
• Clostridium difficile colitis
• Dermatomyositis and polymyositis
• Graves' ophthalmopathy
• Guillain-Barré syndrome
• Muscular Dystrophy
• Inclusion body myositis
• Infertility
• Lambert-Eaton syndrome
• Lupus erythematosus
• Multifocal motor neuropathy
• Multiple sclerosis
• Myasthenia gravis
• Neonatal alloimmune thrombocytopenia
• Parvovirus B19
• Pemphigus
• Post-transfusion purpura
• Renal transplant rejection
• Spontaneous Abortion/Miscarriage
• Sjogren's Syndrome
• Stiff person syndrome
• Opsoclonus Myoclonus
• Severe sepsis and septic shock in critically ill adults
• Toxic epidermal necrolysis
• In chronic lymphocytic leukemia and multiple myeloma, as well as various rare deficiencies of immunoglobulin synthesis (e.g. X-linked agammaglobulinemia, hypogammaglobulinemia), IVIG is administered to maintain adequate immunoglobulin levels to prevent infections.

Complications and side effects

Although routine use of IVIG is common practice, sometimes for long term treatments, and is considered safe, complications of IVIG therapy are known and include:

• headache
• dermatitis - usually peeling of the skin of the palms and soles.
• infection (such as HIV or viral hepatitis) by contaminated blood product; there is also an as of yet unknown risk of contracting variant CJD (vCJD) however the process whereby the product is extracted shows that the contaminants are usually not present in the product.
• pulmonary edema from fluid overload, due to the high colloid oncotic pressure of IVIG
• allergic/anaphylactic reactions; for example, anaphylactic shock, especially in IgA deficient patients, who by definition can still produce IgG antibodies (IgA deficient patients are more likely to produce IgG against the IVIG administration than normal patients).
• damage such as hepatitis caused directly by antibodies contained in the pooled IVIG.
• acute kidney injury
• venous thrombosis
• aseptic meningitis

References

UpToDate Contents

全文を閲覧するには購読必要です。 To read the full text you will need to subscribe.

• 1. 免疫グロブリンの静脈内投与：副作用 intravenous immune globulin adverse effects
• 2. 免疫グロブリンの使用における一般原則 general principles in the use of immune globulin
• 3. 血液疾患における免疫グロブリンの静脈内投与 intravenous immune globulin in hematologic disorders
• 4. 敗血症性ショック：小児における蘇生後の継続的マネージメント septic shock ongoing management after resuscitation in children
• 5. 難治性の尋常性天疱瘡および落葉状天疱瘡のマネージメント management of refractory pemphigus vulgaris and pemphigus foliaceus

English Journal

• Interaction between intravenous immunoglobulin (IVIg) and the low-density lipoprotein receptor-related protein 1: A role for transcytosis across the blood brain barrier?

• Proulx DP, Rouleau P, Paré I, Vallières-Noël MM, Bazin R.SourceDepartment of Research and Development, Héma-Québec, Québec, Canada; Department of Biochemistry and Microbiology, Laval University, Québec, Canada.
• Journal of neuroimmunology.J Neuroimmunol.2012 Oct 15;251(1-2):39-44. Epub 2012 Jul 15.
• Intravenous immunoglobulin (IVIg) is a therapeutic preparation of plasma-derived human IgG and is increasingly used for the treatment of several neurological inflammatory disorders. However, it is not clear whether the IgG molecules contained in IVIg can actually cross the BBB in treated patients. W
• PMID 22796178

• Immunoglobulins in adult sepsis and septic shock.

• Toussaint S, Gerlach H.SourceDepartment of Anesthesia, Critical Care Medicine, and Pain Management, Vivantes - Klinikum Neukoelln, Berlin, Germany.
• Current infectious disease reports.Curr Infect Dis Rep.2012 Oct;14(5):522-9.
• For more than 30 years, intravenously administered immunoglobulins (ivIG) have been used to treat primary and secondary syndromes of immune deficiency. Increasing insight into pathomechanisms of severe sepsis and septic shock have led to the implementation of ivIG therapy in the strategies for adju
• PMID 22886554

Japanese Journal

• 臨床研究報告 慢性移植腎機能低下に対するリツキシマブ,DFPP,IVIG療法の検討

• 石本 達郎,札場 保宏,山下 正博 [他]
• 日本臨床腎移植学会雑誌 = Journal of Japanese Society for Clinical Renal Transplantation 3(1), 92-95, 2015-07
• NAID 40020551338

• 川崎病に対する血漿交換療法の実際(<特集>血管炎症候群とアフェレシス)

• 森口 武史,松田 兼一,針井 則一,後藤 順子,柳沢 政彦,原田 大希,菅原 久徳,星合 美奈子,小泉 敬一
• 日本アフェレシス学会雑誌 34(2), 114-119, 2015-05-31
• … Intravenous immunoglobulin (IVIG) has been improved the outcome of patients with Kawasaki disease. … The efficacy of the treatment of infliximab or apheresis for Kawasaki disease patients who fail to respond to initial IVIG therapy has begun to be accepted recently. … Apheresis for IVIG-resistant Kawasaki disease is effective for preventing coronary artery complications. …
• NAID 110009964085

• 特発性(免疫性)血小板減少性紫斑病および主な先天性(遺伝性)血小板減少症 (特集 私の処方2015) -- (血液疾患の処方)

• 小林 尚明
• 小児科臨床 68(4), 773-779, 2015-04
• NAID 40020401128

Related Links

• IVIG 石川県映像事業協同組合

石川県映像事業協同組合 〒920-0364 石川県金沢市松島2丁目191番地 Image Station COM TEL 076-269-0863 FAX 076-269-8899 E-mail:info@ivig.or.jp

• IVIGスクエア｜免疫グロブリン療法に関する情報提供サイト

IVIGスクエアでは、自己免疫疾患や重症感染症を中心に免疫グロブリン療法のエキスパートの声や最新情報など幅広く掲載していきます。 ... 2015年2月2日付けで「血清IgG2値の低下を伴う、肺炎球菌又はインフルエンザ菌を起炎菌とする ...

Related Pictures

---

★リンクテーブル★

関連記事	「IVIG」「IV」

「IVIG」

　　[★]

• 静注用免疫グロブリン
• 免疫グロブリン静注療法 intravenous immune globulin intravenous immunoglobulin
• 免疫グロブリン補充療法
• 免疫グロブリン大量療法

「IV」

　　[★]

• adj.

• 静脈内の

関

i.v.、intravascular、intravenous、intravenously